This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Plasma proteomics for the identification of Alzheimer disease


Guo, Liang-Hao, Alexopoulos, Panagiotis, Wagenpfeil, Stefan, Kurz, Alexander, Perneczky, Robert


Alzheimer Disease And Associated Disorders, Volume: 27, No.: 4, Pages.: 337-342

Year of Publication



Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. The present study aimed to establish a panel of plasma proteins that accurately distinguishes early AD from physiological aging and to compare the findings with previous reports. Fifty-eight healthy controls (CON) and 109 patients with AD dementia were randomly split into a training (40%) and a test (60%) sample. Significant proteins to differentiate between the CON and AD dementia groups were identified in a comprehensive panel of 107 plasma analytes in the training sample; the accuracy in differentiating these 2 groups was explored in the test sample. A set of 5 plasma proteins was identified, which differentiated between the CON group and the AD dementia group with a sensitivity of 89.36% and a specificity of 79.17%. A biological pathway analysis showed that 4 of 5 proteins belonged to a common network with amyloid precursor protein and tau. Apolipoprotein E was the only protein that was both significant in the present report and in a previous proteomic study. The study provides a piece of evidence in support of the feasibility of a blood-based biomarker approach in AD diagnostics; however, further research is required because of issues with replicability. ;

Bibtex Citation

@article{Guo_2013, doi = {10.1097/wad.0b013e31827b60d2}, url = {}, year = 2013, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {27}, number = {4}, pages = {337--342}, author = {Liang-Hao Guo and Panagiotis Alexopoulos and Stefan Wagenpfeil and Alexander Kurz and Robert Perneczky}, title = {Plasma Proteomics for the Identification of Alzheimer Disease}, journal = {Alzheimer Disease {&} Associated Disorders} }


aged, aged, 80 and over, alzheimer disease, apolipoproteins e, biological markers, biomarkers, blood, blood proteins, cohort studies, diagnosis, female, for, genetics, humans, male, metabolism, methods, proteomics, reproducibility of results

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Biological Testing